{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:07:38Z","timestamp":1781816858256,"version":"3.54.5"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":1838,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Many patients with prior intracerebral haemorrhage have indications for antithrombotic treatment with antiplatelet or anticoagulant drugs for prevention of ischaemic events, but it is uncertain whether such treatment is beneficial after intracerebral haemorrhage. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage will assess (i) the effects of long-term antithrombotic treatment on the risk of recurrent intracerebral haemorrhage and occlusive vascular events after intracerebral haemorrhage and (ii) whether imaging findings, like cerebral microbleeds, modify these effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage is a multicentre, randomised controlled, open trial of starting versus avoiding antithrombotic treatment after non-traumatic intracerebral haemorrhage, in patients with an indication for antithrombotic treatment. Participants with vascular disease as an indication for antiplatelet treatment are randomly allocated to antiplatelet treatment or no antithrombotic treatment. Participants with atrial fibrillation as an indication for anticoagulant treatment are randomly allocated to anticoagulant treatment or no anticoagulant treatment. Cerebral CT or MRI is performed before randomisation. Duration of follow-up is at least two years. The primary outcome is recurrent intracerebral haemorrhage. Secondary outcomes include occlusive vascular events and death. Assessment of clinical outcomes is performed blinded to treatment allocation. Target recruitment is 500 participants.<\/jats:p>\n                    <jats:p>Trial status: Recruitment to STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage is on-going. On 30 April 2020, 44 participants had been enrolled in 31 participating hospitals. An individual patient\u2013data meta-analysis is planned with similar randomised trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2396987320954671","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:41:51Z","timestamp":1599180111000},"page":"414-422","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage: Protocol for a randomised controlled trial"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-8243","authenticated-orcid":false,"given":"Kristin Tveitan","family":"Larsen","sequence":"first","affiliation":[{"name":"Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway 1"},{"name":"University of Oslo, Institute of Clinical Medicine, Oslo, Norway 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Forfang","sequence":"additional","affiliation":[{"name":"University of Oslo, Institute of Clinical Medicine, Oslo, Norway 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Pennlert","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University Hospital, Ume\u00e5, Sweden 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Lotta","family":"Glader","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University Hospital, Ume\u00e5, Sweden 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kruuse","sequence":"additional","affiliation":[{"name":"Herlev Gentofte Hospital and University of Copenhagen, Herlev, Denmark 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Wester","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University Hospital, Ume\u00e5, Sweden 3"},{"name":"Department of Clinical Sciences, Karolinska Institute, Danderyds Hospital, Stockholm, Sweden 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege","family":"Ihle-Hansen","sequence":"additional","affiliation":[{"name":"University of Oslo, Institute of Clinical Medicine, Oslo, Norway 2"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nordland Hospital Trust, Bod\u00f8, Norway 7"},{"name":"Department of Clinical Medicine, UiT The Arctic University of Norway, Troms\u00f8, Norway 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Berge","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustam","family":"Al-Shahi Salman","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgeir","family":"Bruun Wyller","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway 1"},{"name":"University of Oslo, Institute of Clinical Medicine, Oslo, Norway 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5080-5788","authenticated-orcid":false,"given":"Ole Morten","family":"R\u00f8nning","sequence":"additional","affiliation":[{"name":"University of Oslo, Institute of Clinical Medicine, Oslo, Norway 2"},{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Norway 10"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"2026012113165618100_bibr1-2396987320954671","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists Collaboration","year":"2002","journal-title":"BMJ"},{"key":"2026012113165618100_bibr2-2396987320954671","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"2026012113165618100_bibr3-2396987320954671","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026012113165618100_bibr4-2396987320954671","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026012113165618100_bibr5-2396987320954671","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(09)70340-0","article-title":"Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis","volume":"9","author":"van Asch","year":"2010","journal-title":"Lancet Neurol"},{"key":"2026012113165618100_bibr6-2396987320954671","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2013-306476","article-title":"Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis","volume":"85","author":"Poon","year":"2014","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"2026012113165618100_bibr7-2396987320954671","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/STROKEAHA.118.024449","article-title":"Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage","volume":"50","author":"Casolla","year":"2019","journal-title":"Stroke"},{"key":"2026012113165618100_bibr8-2396987320954671","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/STROKEAHA.116.012945","article-title":"Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage","volume":"47","author":"Ottosen","year":"2016","journal-title":"Stroke"},{"key":"2026012113165618100_bibr9-2396987320954671","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1212\/01.wnl.0000250340.05202.8b","article-title":"The increasing incidence of anticoagulant-associated intracerebral hemorrhage","volume":"68","author":"Flaherty","year":"2007","journal-title":"Neurology"},{"key":"2026012113165618100_bibr10-2396987320954671","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/STROKEAHA.113.003003","article-title":"Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands","volume":"45","author":"Schols","year":"2014","journal-title":"Stroke"},{"key":"2026012113165618100_bibr11-2396987320954671","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/STROKEAHA.117.016290","article-title":"Association between previous use of antiplatelet therapy and intracerebral hemorrhage outcomes","volume":"48","author":"Khan","year":"2017","journal-title":"Stroke"},{"key":"2026012113165618100_bibr12-2396987320954671","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/brain\/aws349","article-title":"Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study","volume":"136","author":"Bejot","year":"2013","journal-title":"Brain"},{"key":"2026012113165618100_bibr13-2396987320954671","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1474-4422(07)70107-2","article-title":"Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study","volume":"6","author":"Lovelock","year":"2007","journal-title":"Lancet Neurol"},{"key":"2026012113165618100_bibr14-2396987320954671","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/ijs.12309","article-title":"European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage","volume":"9","author":"Steiner","year":"2014","journal-title":"Int J Stroke"},{"key":"2026012113165618100_bibr15-2396987320954671","first-page":"2032","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage","volume":"46","author":"Hemphill","year":"2015","journal-title":"A guideline for healthcare professionals from the American Heart Association\/American Stroke Association"},{"key":"2026012113165618100_bibr16-2396987320954671","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline","volume":"4","author":"Klijn","year":"2019","journal-title":"Eur Stroke J"},{"key":"2026012113165618100_bibr17-2396987320954671","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/STROKEAHA.114.006202","article-title":"Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage","volume":"45","author":"Pasquini","year":"2014","journal-title":"Stroke"},{"key":"2026012113165618100_bibr18-2396987320954671","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/01.wnl.0000194267.09060.77","article-title":"Antiplatelet use after intracerebral hemorrhage","volume":"66","author":"Viswanathan","year":"2006","journal-title":"Neurology"},{"key":"2026012113165618100_bibr19-2396987320954671","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/STROKEAHA.115.009087","article-title":"Antithrombotic treatment following intracerebral hemorrhage in patients with and without atrial fibrillation","volume":"46","author":"Pennlert","year":"2015","journal-title":"Stroke"},{"key":"2026012113165618100_bibr20-2396987320954671","first-page":"3","article-title":"Oral anticoagulation after intracranial haemorrhage: results of surveys among stroke physicians (Poster Abstract)","volume":"1","author":"Forfang","year":"2016","journal-title":"Eur Stroke J"},{"key":"2026012113165618100_bibr21-2396987320954671","first-page":"Cd012144","article-title":"Antithrombotic treatment after stroke due to intracerebral haemorrhage","volume":"5","author":"Perry","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012113165618100_bibr22-2396987320954671","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/WNL.0b013e3181eee40f","article-title":"Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy","volume":"75","author":"Biffi","year":"2010","journal-title":"Neurology"},{"key":"2026012113165618100_bibr23-2396987320954671","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1160\/TH11-06-0439","article-title":"Use of aspirin in Chinese after recovery from primary intracranial haemorrhage","volume":"107","author":"Chong","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026012113165618100_bibr24-2396987320954671","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/STROKEAHA.110.589143","article-title":"Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage","volume":"41","author":"Flynn","year":"2010","journal-title":"Stroke"},{"key":"2026012113165618100_bibr25-2396987320954671","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.wneu.2017.06.015","article-title":"Antiplatelet resumption after antiplatelet-related intracerebral hemorrhage: a retrospective hospital-based study","volume":"106","author":"Teo","year":"2017","journal-title":"World Neurosurg"},{"key":"2026012113165618100_bibr26-2396987320954671","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2017.11.009","article-title":"Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: a meta-analysis of cohort studies","volume":"384","author":"Ding","year":"2018","journal-title":"J Neurol Sci"},{"key":"2026012113165618100_bibr27-2396987320954671","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1160\/TH17-05-0342","article-title":"Low-dose aspirin after an episode of haemorrhagic stroke is associated with improved survival","volume":"117","author":"Gonzalez-Perez","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026012113165618100_bibr28-2396987320954671","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1212\/WNL.0000000000005742","article-title":"Restarting antiplatelet therapy after spontaneous intracerebral hemorrhage: functional outcomes","volume":"91","author":"Chen","year":"2018","journal-title":"Neurology"},{"key":"2026012113165618100_bibr29-2396987320954671","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"key":"2026012113165618100_bibr30-2396987320954671","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archneur.65.10.1313","article-title":"Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage","volume":"65","author":"Claassen","year":"2008","journal-title":"Arch Neurol"},{"key":"2026012113165618100_bibr31-2396987320954671","first-page":"33","article-title":"Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study","volume":"28","author":"Yung","year":"2012","journal-title":"Can J Cardiol"},{"key":"2026012113165618100_bibr32-2396987320954671","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"2026012113165618100_bibr33-2396987320954671","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"2026012113165618100_bibr34-2396987320954671","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","article-title":"Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage","volume":"133","author":"Chao","year":"2016","journal-title":"Circulation"},{"key":"2026012113165618100_bibr35-2396987320954671","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/WNL.0000000000000245","article-title":"Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study","volume":"82","author":"Poli","year":"2014","journal-title":"Neurology"},{"key":"2026012113165618100_bibr36-2396987320954671","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.25079","article-title":"Oral anticoagulation and functional outcome after intracerebral hemorrhage","volume":"82","author":"Biffi","year":"2017","journal-title":"Ann Neurol"},{"key":"2026012113165618100_bibr37-2396987320954671","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"key":"2026012113165618100_bibr38-2396987320954671","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.0000000000004235","article-title":"Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation","volume":"89","author":"Korompoki","year":"2017","journal-title":"Neurology"},{"key":"2026012113165618100_bibr39-2396987320954671","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/S0140-6736(19)30840-2","article-title":"Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial","volume":"393","author":"Al-Shahi Salman","year":"2019","journal-title":"Lancet"},{"key":"2026012113165618100_bibr40-2396987320954671","author":"Shoamanesh","year":"2020"},{"key":"2026012113165618100_bibr41-2396987320954671","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.115.016261","article-title":"Cerebral microbleeds are associated with an increased risk of stroke: the Rotterdam study","volume":"132","author":"Akoudad","year":"2015","journal-title":"Circulation"},{"key":"2026012113165618100_bibr42-2396987320954671","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fneur.2012.00133","article-title":"Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk","volume":"3","author":"Charidimou","year":"2012","journal-title":"Front Neurol"},{"key":"2026012113165618100_bibr43-2396987320954671","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/01.STR.0000126807.69758.0e","article-title":"Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage","volume":"35","author":"Greenberg","year":"2004","journal-title":"Stroke"},{"key":"2026012113165618100_bibr44-2396987320954671","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(19)30197-8","article-title":"Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies","volume":"18","author":"Wilson","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026012113165618100_bibr45-2396987320954671","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1212\/WNL.0000000000004259","article-title":"Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"key":"2026012113165618100_bibr46-2396987320954671","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2026012113165618100_bibr47-2396987320954671","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026012113165618100_bibr48-2396987320954671","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ane.12185","article-title":"Functioning of long-term survivors of first-ever intracerebral hemorrhage","volume":"129","author":"Tveiten","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"2026012113165618100_bibr49-2396987320954671","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1474-4422(19)30184-X","article-title":"Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial","volume":"18","author":"Al-Shahi Salman","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026012113165618100_bibr50-2396987320954671","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026012113165618100_bibr51-2396987320954671","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2396987320954671","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2396987320954671","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/5\/4\/414\/64649951\/2396987320954671.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/5\/4\/414\/64649951\/2396987320954671.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:19:07Z","timestamp":1769019547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/5\/4\/414\/8271522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1177\/2396987320954671","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]}}}